GHCM
IOVA icon

Glen Harbor Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Glen Harbor Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$12K Sell
640
-112
-15% -$2.48K ﹤0.01% 1315
2019
Q2 		$18K Hold
752
– – ﹤0.01% 1303
2019
Q1 		$7K Sell
752
-80
-10% -$777 ﹤0.01% 1297
2018
Q4 		$7K Buy
+832
New +$8.02K ﹤0.01% 1269

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glen Harbor Capital Management's IOVA Position: Q3 2019 in Review

Glen Harbor Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 15% in Q3 2019, selling an estimated $2.48K and leaving 640 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Glen Harbor Capital Management first reported a position in IOVA in Q4 2018 and has held it in 4 quarters since. The position peaked at $18K in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Glen Harbor Capital Management held 640 shares of Iovance Biotherapeutics worth $12K as of Q3 2019.
  • Glen Harbor Capital Management sold 112 Iovance Biotherapeutics shares in Q3 2019, an estimated $2.48K.
  • Iovance Biotherapeutics made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1315 holding.
  • Glen Harbor Capital Management first reported a position in Iovance Biotherapeutics in Q4 2018 and has held it in 4 quarters since.
  • Glen Harbor Capital Management's Iovance Biotherapeutics position peaked at $18K in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.